Skip to content

Gross margin at other companies

Eli Lilly logo
Eli LillyLLY
82.8%+1.1pp
Pfizer logo
PfizerPFE
73.5%+1.2pp
Merck & Co. logo
Merck & Co.MRK
73.9%-2.5pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
86.2%+0.2pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
86.1%+7.2pp
Mannkind logo
MannkindMNKD
91.5%-2.6pp

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+262%
Enterprise value$976.73M+209%
P/S14.2×+5.4×

Profitability

See full
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Calculated from Lexicon Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's gross margin?
Lexicon Pharmaceuticals (LXRX) reported gross margin of 99.5% in Q1 2026.
How has Lexicon Pharmaceuticals's gross margin changed year-over-year?
Lexicon Pharmaceuticals's gross margin increased by 1.5% year-over-year, from 98% to 99.5%.
What is the long-term trend for Lexicon Pharmaceuticals's gross margin?
Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's gross margin has grown at a 1.6% compound annual growth rate (CAGR), from 92% to 99.4%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.